|
Proof of concept for an improved twice-daily controlled-release
formulation of morphine.
Egalet a/s has demonstrated proof of concept for an improved
twice-daily controlled-release formulation of morphine.
Successful studies with the new formulation based on the
patented Egalet® technology shows pain relief
comparable with conventional morphine sustained release products
on the market, and at the same time a tendency towards fewer
adverse effects is seen in the group of patients receiving the
Egalet® formulation. Plasma measurements have also demonstrated
fewer fluctuations in the concentrations of morphine in the
Egalet® treated group.
The new morphine formulation is developed by Egalet a/s and
utilises the Egalet® zero order release technology named as 2K for the controlled
delivery. |